503000-87-1

Basic information

• Product Name: 2-CHLORO-6-METHOXYNICOTINIC ACID
• Synonyms: 2-CHLORO-6-METHOXYNICOTINIC ACID;2-Chloro-6-methoxypyridine-3-carboxylic acid;2-Chloro-6-methoxypyridine-3-carboxylic acid, 3-Carboxy-2-chloro-6-methoxypyridine
• CAS NO: 503000-87-1
• Molecular Formula: C₇H₆ClNO₃
• Molecular Weight: 187.58
• Mol File: 503000-87-1.mol

Chemical Properties

• Melting Point: 231-234℃
• Boiling Point: 310.391 °C at 760 mmHg
• Flash Point: 141.52 °C
• Appearance: /
• Density: 1.43 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.41±0.28(Predicted)
• CAS DataBase Reference: 2-CHLORO-6-METHOXYNICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-6-METHOXYNICOTINIC ACID(503000-87-1)
• EPA Substance Registry System: 2-CHLORO-6-METHOXYNICOTINIC ACID(503000-87-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 503000-87-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 46, p. 702, 2003 DOI: 10.1021/jm020270n

InChI:InChI=1/C7H6ClNO3/c1-12-5-3-2-4(7(10)11)6(8)9-5/h2-3H,1H3,(H,10,11)

Upstream product

• 67-56-1 methanol 
• 55366-30-8 2,6-dichloro-3-(trichloromethyl)pyridine 
• 95652-77-0 methyl 2-chloro-6-methoxypyridine-3-carboxylate 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 95652-76-9 2-chloro-6-methoxy-3-(trimethoxymethyl)pyridine 
• 97985-23-4 methyl 2,6-dichloro-1-oxidopyridine-3-carboxylate 
• 124-41-4 sodium methylate 
• 911801-63-3 2,6-dichloro-3-trichloromethylpyridine N-oxide 

Downstream Products

• 95652-77-0 methyl 2-chloro-6-methoxypyridine-3-carboxylate 
• 503000-88-2 methyl 6-methoxy-2-methylaminopyridine-3-carboxylate 
• 503000-90-6 5-chloro-6-methoxy-2-methylaminopyridine-3-carboxylic acid 
• 503000-89-3 methyl 5-chloro-6-methoxy-2-methylaminopyridine-3-carboxylate 
• 1171823-22-5 2-chloro-5-bromo-6-methoxypyridine-3-carboxylic acid 
• 1171823-27-0 1-[(S)-1-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-propyl]-6-(3-chloro-2-fluoro-benzyl)-7-methoxy-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid ethyl ester 
• 1304702-20-2 C₂₈H₃₆ClFN₂O₅Si 
• 1304702-35-9 C₂₉H₃₈ClFN₂O₅Si 
• 1304702-51-9 C₃₀H₄₀ClFN₂O₅Si 
• 1304702-62-2 C₃₁H₄₂ClFN₂O₅Si 
• 1304702-63-3 C₃₁H₄₂ClFN₂O₅Si 
• 1266162-24-6 C₂₃H₂₄ClFN₂O₅ 
• 1304702-66-6 C₃₁H₄₂ClFN₂O₅Si 
• 1171821-11-6 C₂₃H₂₄ClFN₂O₅ 

Relevant articles and documents

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors

Integrase mutations can reduce the effectiveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG). The second-generation agent, dolutegravir (DTG), has enjoyed considerable clinical success; however, resistance-causing mutations that diminish the efficacy of DTG have appeared. Our current findings support and extend the substrate envelope concept that broadly effective INSTIs can be designed by filling the envelope defined by the DNA substrates. Previously, we explored 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides as an INSTI scaffold, making a limited set of derivatives, and concluded that broadly effective INSTIs can be developed using this scaffold. Herein, we report an extended investigation of 6-substituents as well the first examples of 7-substituted analogues of this scaffold. While 7-substituents are not well-tolerated, we have identified novel substituents at the 6-position that are highly effective, with the best compound (6p) retaining better efficacy against a broad panel of known INSTI resistant mutants than any analogues we have previously described.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation-incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

Halogenated allyl amine type SSAO/VAP-1 inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a halogenated allyl amine type compound shown as a formula I, medically acceptable salt, ester or stereo isomers thereof, wherein R1, R2, R3, R4, R5, R6, L1, Cy1, R7 and p are defined in description. The invention also relates to a medicine preparation containing the compounds, a medicine composition containing the compounds, and application of the compounds to prevention and/or treatment on diseases relevant to SSAO/VAP 1 protein or diseases caused by SSAO/VAP 1 protein mediating. The formula I is shown in the description.

ARYLCARBOXAMIDES AND USES THEREOF

The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic diseases such as scleroderma; lung disease, such as pulmonary fibrosis including idiopathic pulmonary fibrosis (IPF); heart disease, such as heart failure due to ischaemic heart disease, valvular heart disease and hypertensive heart disease, diabetic cardiomyopathy and hypertension; liver disease, such as cirrhosis of the liver; and kidney disease, such as progressive kidney disease glomerulonephritis and diabetic nephropathy; and eye disease such as diabetic retinopathy; skin or subcutaneous scarring, such as keloids, adhesions, hypertrophic scarring or cosmetic scarring; or as an adjuvant or anti-fibrotic in pancreatic cancer to increase chemotherapeutic drug penetration by reducing the density of the connective tissue stroma.

EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

AROMATIC COMPOUND

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.